To validate our findings of MGMT inhibition by hGTX and nitrosylating compounds in preclinical settings, we developed subcutaneous xenografts by injecting many MGMT proficient cell lines in female nu/nu mice and determined the antitumor efficacy and MGMT activity and protein levels in clarified tumor lysates. The gene discussed is MGMT; the disease is neoplasm.